NY-SERMO
16.3.2022 14:02:09 CET | Business Wire | Press release
A new survey from Sermo , a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.
81% of physicians reported feeling that social media misinformation has caused an existential crisis in their profession. More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine. Also, more than half (55%) of physicians reported that COVID-19 vaccine misinformation is increasingly becoming an issue when meeting with patients.
Physicians are being bombarded with a variety of COVID-19 vaccine misinformation. The most common misinformation they are hearing from patients is that vaccine safety and effectiveness cannot be trusted because researchers rushed the development of the vaccine, reported by 60% of physicians.
Other types of misinformation heard by physicians from patients include:
- More than half (51%) of physicians reported hearing from patients that they don’t need a COVID-19 vaccine if they’ve already had Covid.
- Misinformation about vaccines modifying your DNA continues to prevail. 45% of physicians reported hearing this from patients.
- Conspiracy theories about microchips in vaccines have made their way to the doctor’s office as 29% of physicians reported hearing this from patients.
- 1 in 5 (20%) physicians reported hearing from patients that the COVID-19 vaccine gives you COVID-19.
- One-third of physicians (34%) reported hearing from patients that vaccines cause infertility. Physicians feel that vaccine hesitancy among pregnant women persists. 61% of physicians reported that pregnant patients are reluctant to get the vaccine.
- COVID-19 vaccine hesitancy is spilling over to other vaccines. 52% of surveyed physicians feel patients who have been hesitant to get COVID-19 vaccines will stop getting other vaccines.
“It’s clear from when we first launched the COVID-19 barometer at the start of the pandemic that misinformation is increasingly posing huge challenges to physicians when treating patients. Physicians feel like they are battling an infodemic that is threatening public health,” says Peter Kirk, Sermo CEO. “The barometer results clearly paint a picture that misinformation is showing up at appointments across the U.S. and the globe at a very local level.”
In addition to battling COVID-19 misinformation, surveyed physicians continue to report they are seeing a significant amount of reluctance among parents to get their kids vaccinated. 61% of physicians reported seeing patients more reluctant to vaccinate their children than themselves. Lack of long-term vaccine safety data in children (45%) was the leading reason physicians believed parents were reluctant to vaccinate their children. This is an increase from a previous Barometer survey fielded in November 2021 when 38% of physicians believed that lack of long-term vaccine safety data was keeping parents from vaccinating their children. 1 in 4 (23%) physicians believed that adverse effects and allergic reactions were a reason that parents weren’t vaccinating their children.
This survey was fielded as part 22 of Sermo’s COVID-19 Barometer and included more than 3,600 physician respondents between March 2 - March 3, 2022. To find out more about the findings of Sermo’s latest COVID-19 Real Time Barometer, visit app.sermo.com/covid19-barometer .
About Sermo:
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infopro Digital Automotive Highlights Its Industry-Leading Datasets at Automechanika 202626.8.2026 10:02:00 CEST | Press release
Infopro Digital Automotive, leader in data and software for the automotive market, announces its participation in Automechanika 2026, the world’s leading trade fair for the automotive industry. After completing several significant acquisitions over the past years, including Eucon, GiPA, and Aurelis last September, the company will attend this year’s trade show with a consolidated offering, built upon its trusted industry-leading datasets. Infopro Digital Automotive now addresses every automotive vertical from independent workshops to parts, tyres and car manufacturers, through the whole network of aftermarket distribution professionals, thus delivering to them key data and integrated digital solutions to power strategic decisions at every step of the vehicle lifecycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826133342/en/ Infopro Digital Automotive’s unmatched dataset portfolio will be presented at Automechanika 20
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles26.8.2026 10:01:00 CEST | Press release
- Addressing the Global Rise in Diabetes - NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its "Ultra-thin and narrow-width stainless steel" optimized for laser welding in ultra-fine insulin needles. In response to growing global demand, the company has established a stable supply system for these high-quality materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826770424/en/ The scale of the global diabetes crisis is expanding. In line with this trend, the global demand for insulin needles continues to escalate. Furthermore, insulin delivery is evolving toward "painless" experiences that reduce patient burden. Modern designs prioritize minimizing pain and bruising, leading to the widespread adoption of ultra-fine needles. This trend is further supported by the growing popularity of compact, portable pe
VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data26.8.2026 10:00:00 CEST | Press release
VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. VirTus has worked on the APL-10456 programme for more than five years, conducting more than 20 preclinical studies to support the selection, development and progression of the candidate, testing the cross-species immunogenicity and efficacy. This work included evaluating the efficacy of several vaccine candidates in mouse models of rhinovirus infection, helping to select APL-10456 and establish early proof of concept and generating preclinical evidence that informed its progression into first-in-human clinical development. APL-10456 is a first-in-class, adjuvanted recombinant protein subunit
Xsolla President Chris Hewish Debuts “Durable Advantage” at Gamescom 202626.8.2026 09:00:00 CEST | Press release
Book Draws on Chris Hewish’s Three Decades of Leadership in the Global Games Industry, Grounded in “Renters vs. Owners” Theory and Five-Pillars for Scaling and Succeeding Xsolla, a leading global commerce company, today announced Durable Advantage: Five Pillars of the Modern Game Business, a new book authored by Chris Hewish, President of Xsolla, launching at Gamescom 2026 in Cologne. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826628682/en/ Graphic: Xsolla Xsolla's integrated strategy brings together global payments, direct-to-consumer commerce, backend infrastructure, and AI-powered development tools into a unified operating model designed to help studios launch, operate, and scale more efficiently. Rather than relying on disconnected commerce, engagement, and backend systems, developers can activate new capabilities through a common platform foundation that reduces complexity, accelerates deployment, and creates a m
David Hagan, Dean and Pegasus Professor at CREOL, The College of Optics and Photonics, Will Serve as Vice President of SPIE26.8.2026 05:00:00 CEST | Press release
Newly elected SPIE board members bring distinct backgrounds to optics and photonics community David Hagan has been elected to serve as the 2027 Vice President of SPIE, the international society for optics and photonics. He will serve as President-Elect in 2028, and as the Society’s President in 2029. The SPIE Board of Directors is influential in the scientific community, establishing policy and strategy and conducting activities of interest to SPIE Members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825934622/en/ Top row, from left to right: David Hagan, Jim McNally, Mark Clampin. Bottom row, from left to right: Marla Dowell, Jana Kainerstorfer, Katie Schwertz The 2026 SPIE President, Julie Bentley, professor of optics at the University of Rochester, made the new electees announcement at the Annual General Meeting of the Society on 25 August during SPIE Optics + Photonics. Terms begin on 1 January 2027. In addition to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
